Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Baxter
Argus Health
Daiichi Sankyo
Healthtrust
Cantor Fitzgerald
Chubb

Generated: June 23, 2018

DrugPatentWatch Database Preview

ALLERGAN SALES LLC Company Profile

« Back to Dashboard

Summary for ALLERGAN SALES LLC
International Patents:948
US Patents:61
Tradenames:52
Ingredients:38
NDAs:52
Drug Master File Entries: 1
Patent Litigation for ALLERGAN SALES LLC: See patent lawsuits for ALLERGAN SALES LLC

Drugs and US Patents for ALLERGAN SALES LLC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No 7,888,342 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc NAMENDA memantine hydrochloride SOLUTION;ORAL 021627-001 Apr 18, 2005 DISCN Yes No ➤ Sign Up ➤ Sign Up
Allergan Sales Llc BREVICON 28-DAY ethinyl estradiol; norethindrone TABLET;ORAL-28 017743-001 Approved Prior to Jan 1, 1982 AB RX No No ➤ Sign Up ➤ Sign Up
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No 7,179,483 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ALLERGAN SALES LLC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc DILACOR XR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020092-002 May 29, 1992 5,422,123 ➤ Sign Up
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-003 Dec 20, 1996 5,122,383 ➤ Sign Up
Allergan Sales Llc BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-005 Oct 8, 2008 5,759,580 ➤ Sign Up
Allergan Sales Llc ANDRODERM testosterone FILM, EXTENDED RELEASE;TRANSDERMAL 020489-001 Sep 29, 1995 5,152,997 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN SALES LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09

Non-Orange Book US Patents for ALLERGAN SALES LLC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,087,241 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
8,980,290 Transdermal compositions for anticholinergic agents ➤ Sign Up
9,259,403 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide ➤ Sign Up
8,652,491 Transdermal compositions for anticholinergic agents ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ALLERGAN SALES LLC Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00053 Denmark ➤ Sign Up PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
C/GB13/004 United Kingdom ➤ Sign Up PRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/12/785/001 20120823
2016 00059 Denmark ➤ Sign Up PRODUCT NAME: FARMACEUTISK BLANDING ELLER SAMMENSAETNING DER SOM AKTIVE BESTANDDELE DERAF, HERUNDER CEFTAZIDIMPENTAHYDRAT OG AVIBACTAMNATRIUM; REG. NO/DATE: EU/1/16/1109 20160628
13/044 Ireland ➤ Sign Up PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Baxter
Chubb
Accenture
McKesson
Citi
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.